Literature DB >> 32146229

Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling.

Roger L Papke1, Jon M Lindstrom2.   

Abstract

Postsynaptic nAChRs in the peripheral nervous system are critical for neuromuscular and autonomic neurotransmission. Pre- and peri-synaptic nAChRs in the brain modulate neurotransmission and are responsible for the addictive effects of nicotine. Subtypes of nAChRs in lymphocytes and non-synaptic locations may modulate inflammation and other cellular functions. All AChRs that function as ligand-gated ion channels are formed from five homologous subunits organized to form a central cation channel whose opening is regulated by ACh bound at extracellular subunit interfaces. nAChR subtype subunit composition can range from α7 homomers to α4β2α6β2β3 heteromers. Subtypes differ in affinities for ACh and other agonists like nicotine and in efficiencies with which their channels are opened and desensitized. Subtypes also differ in affinities for antagonists and for positive and negative allosteric modulators. Some agonists are "silent" with respect to channel opening, and AChRs may be able to signal metabotropic pathways by releasing G-proteins independent of channel opening. Electrophysiological studies that can resolve single-channel openings and molecular genetic approaches have allowed characterization of the structures of ligand binding sites, the cation channel, and the linkages between them, as well as the organization of AChR subunits and their contributions to function. Crystallography and cryo-electron-microscopy are providing increasing insights into the structures and functions of AChRs. However, much remains to be learned about both AChR structure and function, the in vivo functional roles of some AChR subtypes, and the development of better pharmacological tools directed at AChRs to treat addiction, pain, inflammation, and other medically important issues. This article is part of the special issue on 'Contemporary Advances in Nicotine Neuropharmacology'.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32146229      PMCID: PMC7610230          DOI: 10.1016/j.neuropharm.2020.108021

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  25 in total

Review 1.  Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity.

Authors:  Namrita Halder; Girdhari Lal
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

Review 2.  α7 nicotinic acetylcholine receptors in the hippocampal circuit: taming complexity.

Authors:  Ayland C Letsinger; Zhenglin Gu; Jerrel L Yakel
Journal:  Trends Neurosci       Date:  2021-12-13       Impact factor: 13.837

3.  A Functional Interaction Between Y674-R685 Region of the SARS-CoV-2 Spike Protein and the Human α7 Nicotinic Receptor.

Authors:  Juan Facundo Chrestia; Ana Sofia Oliveira; Adrian J Mulholland; Timothy Gallagher; Isabel Bermúdez; Cecilia Bouzat
Journal:  Mol Neurobiol       Date:  2022-07-20       Impact factor: 5.682

Review 4.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

Review 5.  Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.

Authors:  Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney
Journal:  Rev Endocr Metab Disord       Date:  2020-08-26       Impact factor: 6.514

6.  Novel Spiropiperidine Allosteric Modulators of Nicotinic Acetylcholine Receptors for Treating Central Nervous System Disorders.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-01-11       Impact factor: 4.345

Review 7.  Novel Pharmacotherapies in Parkinson's Disease.

Authors:  Yousef Tizabi; Bruk Getachew; Michael Aschner
Journal:  Neurotox Res       Date:  2021-05-18       Impact factor: 3.911

8.  Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm.

Authors:  Jesus Gonzalez-Rubio; Carmen Navarro-Lopez; Elena Lopez-Najera; Ana Lopez-Najera; Lydia Jimenez-Diaz; Juan D Navarro-Lopez; Alberto Najera
Journal:  Front Immunol       Date:  2020-06-11       Impact factor: 7.561

9.  The selective alpha7 nicotinic acetylcholine receptor agonist AR-R17779 does not affect ischemia-reperfusion brain injury in mice.

Authors:  Maria E Hammarlund; Vladimer Darsalia; Filip Mjörnstedt; Bagmi Pattanaik; Carina Mallard; Eridan Rocha-Ferreira; Cesare Patrone; Maria E Johansson
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

Review 10.  Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors.

Authors:  Roger L Papke; Nicole A Horenstein
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.